Mesenchymal stem cells are the most-studied cell type in regenerative medicine and the most-marketed. Understanding the biology, the reason 'stem cell' is now a partial misnomer, and the U.S. regulatory environment is critical for any practice claiming to work in this space.
What MSCs actually are
The International Society for Cellular Therapy defines MSCs by three criteria: plastic adherence in culture, specific surface marker expression (CD73+, CD90+, CD105+, lacking CD45/CD34/CD14/CD11b/CD79α/CD19/HLA-DR), and tri-lineage differentiation potential toward osteogenic, chondrogenic, and adipogenic lineages. In the last decade the field has largely dropped "stem" in favor of "medicinal signaling cells" to reflect the dominant paracrine mode of action.
Source tissues
- Bone marrow — the classical source; declining MSC content with age.
- Adipose tissue — higher MSC yield per gram, easier harvest, growing evidence base for culture-expanded products.
- Umbilical cord tissue (Wharton's jelly) — highest proliferation potential, allogeneic.
- Placenta and amniotic membrane — allogeneic, immunoprivileged.
- Dental pulp — a growing area of investigation.
Mechanism of action, in order of therapeutic contribution
- Paracrine signaling: secretion of growth factors, cytokines, and extracellular vesicles that modulate the wound-healing environment. Now understood as the dominant mode of action.
- Immunomodulation: shift of macrophages toward M2, T-cell suppression, T-regulatory promotion. Basis for MSC use in graft-vs-host disease and autoimmune research.
- Homing: migration to sites of injury via SDF-1/CXCR4 chemokine axis.
- Extracellular matrix modification: deposition of matrix proteins, release of matrix metalloproteinases.
- Direct differentiation: occurs but is now recognized as a minor contributor in most adult regenerative contexts.
Culture expansion changes the product
Ex-vivo expansion multiplies MSC yield by many orders of magnitude and enables dose standardization — but under U.S. law it moves the product from same-day autologous minimally manipulated territory into biologic drug territory, requiring IND investigation and eventual BLA approval. This is the pivotal regulatory distinction that shapes what U.S. clinics can and cannot offer.
Regulatory landscape in 2026
- Same-day autologous minimally manipulated MSCs (e.g., BMAC): legal for homologous use under 21 CFR 1271.
- Culture-expanded autologous MSCs: considered more-than-minimally manipulated; require IND for U.S. clinical use.
- Culture-expanded allogeneic MSCs: considered biologic drugs; several products advancing through Phase III for specific indications (GvHD, Crohn's fistulas, knee OA).
- International practice: multiple countries allow culture-expanded MSC therapy under different regulatory schemes. U.S. patients traveling for these therapies is common; providers should discuss the framing candidly.
Evidence base by indication
- Graft-vs-host disease: approved MSC products available in several markets; strong evidence for steroid-refractory acute GvHD.
- Perianal Crohn's fistulas: an approved MSC product with strong clinical outcomes.
- Knee osteoarthritis: promising Phase II/III data with culture-expanded allogeneic MSCs; awaiting broader approval.
- Osteonecrosis, non-union, chronic wounds: supportive evidence for same-day autologous (BMAC-based) use.
The "MSC infusion" problem
IV infusion of MSCs for systemic anti-aging or degenerative disease modification is heavily marketed and poorly supported. Injected MSCs are largely trapped in the pulmonary microvasculature within hours and cleared within days. Whether transient paracrine effects justify the intervention outside a clinical trial is an open question — one that current U.S. FDA framing answers in the negative for culture-expanded product outside an IND.
What providers should understand
- Not all "MSC" products are what they claim — ask for characterization data.
- Autologous minimally manipulated MSC preparations are legal and useful.
- Culture-expanded and allogeneic MSCs sit in regulatory review.
- Marketing of systemic MSC infusion in the U.S. warrants scrutiny.